Buchumschlag

Health-related quality of life in multiple myeloma patients treated with high- or low-dose lenalidomide maintenance therapy after autologous stem cell transplantation: results from the LenaMain trial (NCT00891384)

Introduction: The LenaMain trial (NCT00891384) reported increased progression-free survival with 25 mg of lenalidomide maintenance compared to 5 mg. Here, we report the patient-reported outcomes. Materials and Methods: Scores obtained from the EORTC Quality of Life Questionnaire C30 were analyzed fo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Boquoi, Amelie (VerfasserIn) , Giagounidis, Aristoteles (VerfasserIn) , Goldschmidt, Hartmut (VerfasserIn) , Heinsch, Michael (VerfasserIn) , Rummel, Mathias J. (VerfasserIn) , Kröger, Nicolaus (VerfasserIn) , Mai, Elias K. (VerfasserIn) , Strapatsas, Judith (VerfasserIn) , Haas, Rainer (VerfasserIn) , Kobbe, Guido (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 26 October 2023
In: Cancers
Year: 2023, Jahrgang: 15, Heft: 21, Pages: 1-17
ISSN:2072-6694
DOI:10.3390/cancers15215157
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/cancers15215157
Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2072-6694/15/21/5157
Volltext
Verfasserangaben:Amelie Boquoi, Aristoteles Giagounidis, Hartmut Goldschmidt, Michael Heinsch, Mathias J. Rummel, Nicolaus Kröger, Elias K. Mai, Judith Strapatsas, Rainer Haas and Guido Kobbe
Beschreibung
Zusammenfassung:Introduction: The LenaMain trial (NCT00891384) reported increased progression-free survival with 25 mg of lenalidomide maintenance compared to 5 mg. Here, we report the patient-reported outcomes. Materials and Methods: Scores obtained from the EORTC Quality of Life Questionnaire C30 were analyzed for longitudinal changes from baseline within the groups as well as cross-sectional scores. Results: Compliance rates were high, with 95.7% at baseline and 70% during maintenance. At study entry, scores were high for functioning and low for symptoms. During maintenance, the median global health status/quality of life (GHS/QoL) was constant, without significant differences over time (median GHS/QoL: 68 at baseline and 58 for Len high and 68 for Len low at 2 years) and between treatment arms (mean change < 2). Similarly, most functional scale domains were constant. Notably, diarrhea increased consistently for both treatment arms (baseline: −1.905 (range: −5.78-1.97); end of year 2: 16.071 (range: 5.72-26.42); p < 0.05). The subgroup analysis showed that neither disease activity, duration of treatment, nor adverse events affected the health-related quality of life (HR-QoL) or utility. Conclusion: High baseline scores were maintained throughout the trial without significant differences between the Len dosages, which supports continuous treatment with a dose tailored to patients’ HR-QoL.
Beschreibung:Gesehen am 17.05.2024
Beschreibung:Online Resource
ISSN:2072-6694
DOI:10.3390/cancers15215157

Ähnliche Einträge